FIELD: medicine; pharmaceuticals.
SUBSTANCE: invention relates to a pharmaceutical composition, in particular to a pharmaceutical combination for the treatment of type 2 diabetes. Disclosed are: a pharmaceutical combination for the treatment of diabetes mellitus type 2, comprising a pharmaceutical composition containing lixisenatide or / and a pharmaceutically acceptable salt thereof, insulin glargine or / and a pharmaceutically acceptable salt thereof, taken in certain concentrations; and metformin and / or a pharmaceutically acceptable salt thereof; use of a pharmaceutical combination for the treatment of type 2 diabetes mellitus and a method for the treatment of type 2 diabetes mellitus, comprising administering to a subject in need thereof a pharmaceutical composition, wherein the pharmaceutical composition is administered as an adjunct to treatment with metformin or / and pharmaceutically acceptable salt thereof.
EFFECT: disclosed pharmaceutical combination for the treatment of type 2 diabetes mellitus is an effective combination as an adjunct to treatment with metformin or / and pharmaceutically acceptable salt thereof.
16 cl, 5 dwg, 21 tbl, 2 ex
